The elderly safety imperative and antipsychotic usage

Harvard Review of Psychiatry

Volumn 18, Issue 3, 2010, Pages 158-172

  Chahine, Lama M ^a   Acar, Diler ^b   Chemali, Zeina ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotics; Dementia; Geriatrics; Psychosis; Safety

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DONEPEZIL; HALOPERIDOL; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; AGRANULOCYTOSIS; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; APATHY; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DELIRIUM; DEMENTIA; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ELDERLY CARE; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FALLING; HEART VENTRICLE ARRHYTHMIA; HEAT STROKE; HUMAN; HYPOTHERMIA; INTERPERSONAL COMMUNICATION; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; MAJOR DEPRESSION; MASSAGE; META ANALYSIS; METABOLIC SYNDROME X; MOOD DISORDER; MORTALITY; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PNEUMONIA; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; STROKE; SYMPTOMATOLOGY; SYNCOPE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT RESPONSE; URINE RETENTION; WEIGHT GAIN;

AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COGNITION; DEMENTIA; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; SCHIZOPHRENIA;

EID: 77951761692     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673221003747690     Document Type: Review

References (153)

1. Broadway J, Mintzer J. The many faces of psychosis in the elderly. Curr Opin Psychiatry 2007;20:551-558
2. Shen WW. A history of antipsychotic drug development. Compr Psychiatry 1999;40:407-414
3. Bonham C, Abbott C. Are second generation antipsychotics a distinct class? J Psychiatr Pract 2008;14:225-231
4. Mintzer J, Targum SD. Psychosis in elderly patients: classification and pharmacotherapy. J Geriatr Psychiatry Neurol 2003;16:199-206.
5. Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother 2008;6:187-197
6. Lovheim H, Karlsson S, Gustafson Y. The use of central nervous system drugs and analgesics among very old people with and without dementia. Pharmacoepidemiol Drug Saf 2008;17:912-918
7. Alanen HM, Finne-Soveri H, Fialova D, et al. Use of antipsychotic medications in older home-care patients. Report from nine European countries. Aging Clin Exp Res 2008;20:260-265
8. Jano E, Johnson M, Chen H, Aparasu RR. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin 2008;24:709-716
9. Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008;69:240-245
10. Bret MC, Bret P, Pariente A, Fourier-Reglat A. The use of atypical antipsychotics in French psychiatric hospitals. Pharm World Sci 2007;29:551-556
11. Giblin S, Clare L, Livingston G, Howard R. Psychosocial correlates of late-onset psychosis: life experiences, cognitive schemas, and attitudes to ageing. Int J Geriatr Psychiatry 2004;19:611-623
12. McKneal KM, Meyer RP, Lukacs K, Senseney A, Mintzer J. Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opin Pharmacother 2008;9:2537-2543
13. Schoenmakers B, Buntinx F, De Lepeleire J. Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver? Fam Pract 2009;26:279-286
14. Slattum PW, Johnson MA. Caregiver burden in Alzheimer's disease. Consult Pharm 2004;19:352-362
15. Lovheim H, Sandman PO, Kallin K, Karlsson S, Gustafson Y. Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr 2006;18:713-726
16. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998;155:1512-1520
17. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-115
18. De Deyn PP, Katz IR. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry 2000;15 suppl 1:S14-22.
19. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955
20. Brodaty H, Ames D, Snowdon J, et al. A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-143
21. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005;107:497-508.
22. Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry 2006;14:280-291
23. Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry 2003;11:414-425
24. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a metaanalysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 2007;22:475-484
25. Schneider LS, Tariot PN, Dagerman KS, et al; CATIEAD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-1538
26. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006;14:767-776
27. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res 2007;4:81-93.
28. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:115-126
29. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a doubleblind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57:968-976
30. Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: amulticenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007;15:918-931
31. Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008;16:537-550
32. De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 2005;25:463-467
33. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004;45:297-301.
34. Parellada E, Baeza I, de Pablo J, Martinez G. Risperidone in the treatment of patients with delirium. J Clin Psychiatry 2004;65:348-353
35. Hwang JP, Yang CH, Lee TW, Tsai SJ. The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol 2003;23:113-118
36. Howanitz E, Pardo M, Smelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 1999;60:41-44
37. Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003;18:1013-1020
38. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003;11:638-647
39. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;8:29-34.
40. Jeste DV, Blazer D, Casey D, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008;33:957-970
41. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-1483
42. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-714
43. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. CochraneDatabase Syst Rev 2001;(4):CD002852.
44. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
45. Ballard C, Hanney ML, Theodoulou M, et al; DART-AD investigators. The dementia antipsychotic withdrawal trial (DARTAD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009;8:151-157
46. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156-1162
47. Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry 2004;65:1708-1714
48. Rainer M, Haushofer M, Pfolz H, Struhal C, Wick W. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Eur Psychiatry 2007;22:395-403.
49. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005;330:874.
50. Kurlan R, Cummings J, Raman R, Thal L; Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356-1363
51. Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes-a 12-month follow-up study. Am J Geriatr Psychiatry 2008;16:528-536
52. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008;69:889-898
53. Kessing LV. Differences in diagnostic subtypes among patients with late and early onset of a single depressive episode. Int J Geriatr Psychiatry 2006;21:1127-1131
54. O'Connor DW, Gardner B, Presnell I, Singh D, Tsanglis M, White E. The effectiveness of continuation-maintenance ECT in reducing depressed older patients' hospital re-admissions. J Affect Disord 2010;120:62-66
55. Wilkins KM, Ostroff R, Tampi RR. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. J Geriatr Psychiatry Neurol 2008;21:3-11.
56. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-991
57. Sheffrin M, Driscoll HC, Lenze EJ, et al. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. J Clin Psychiatry 2009;70:208-213
58. Holroyd S, Laurie S. Correlates of psychotic symptoms among elderly outpatients. Int J Geriatr Psychiatry 1999;14:379-384
59. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007;(2):CD005594.
60. Attard A, Ranjith G, Taylor D. Delirium and its treatment. CNS Drugs 2008;22:631-644
61. Harris MJ, Jeste DV. Late-onset schizophrenia: an overview. Schizophr Bull 1988;14:39-55.
62. Howard R, Rabins PV, Seeman MV, Jeste DV. Lateonset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry 2000;157:172-178
63. Sato T, Bottlender R, Schroter A, Moller HJ. Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. Schizophr Res 2004;67:175-183
64. Girard C, SimardM. Clinical characterization of late- and very late-onset first psychotic episode in psychiatric inpatients. Am J Geriatr Psychiatry 2008;16:478-487
65. Kissling W, Glue P, Medori R, Simpson S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 2007;22:505-513
66. Tadger S, Baruch Y, Barak Y. Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone. Int Psychogeriatr 2008;20:1245-1250
67. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008;337:a1227.
68. Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry 2004;65 suppl 2:5-99; discussion 100-2; quiz 103-104
69. Madhusoodanan S, Sinha A, Sajatovic M, Gupta S, Brenner R. The role of atypical antipsychotic agents in the treatment of schizophrenia and schizoaffective disorders in the elderly. Curr Drug Saf 2006;1:227-241
70. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-786
71. Singh S, Wooltorton E. Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ 2005;173:252.
72. U.S. Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. http://www.fda.gov/ Drugs/DrugSafety/PublicHealthAdvisories/UCM053171
73. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a populationbased time-series analysis. CMAJ 2008;179:438-446
74. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943
75. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341
76. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005;165:696-701.
77. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry 2004;12:437-439
78. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999;60:292-298
79. Setoguchi S,Wang PS, Alan Brookhart M, Canning CF,Kaci L, Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008;56:1644-1650
80. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol 2007;27:707-710
81. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395.
82. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-1270
83. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008;23 suppl 1:3-14.
84. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005;165:2677-2682 (Pubitemid 41785068)
85. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005;17:617-629
86. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445.
87. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005;66:1090-1096
88. Sacchetti E, Trifiro G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008;22:39-46.
89. Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol 2005;19:473-482
90. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol 2009;23:909-914
91. Barak Y, Baruch Y,Mazeh D, Paleacu D, AizenbergD. Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. Am J Geriatr Psychiatry 2007;15:354-356
92. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 2007;15:416-424
93. Goldstein LB, Adams R, Alberts MJ, et al; American Heart Association/American Stroke Association Stroke Council; Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Academy of Neurology. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583-1633
94. Adams RJ, Albers G, AlbertsMJ, et al.; American Heart Association; American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-1652
95. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997;314:266-270
96. DeberdtWG, Siegal A, Ahl J, Meyers AL, Landbloom R. Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis. Int J Geriatr Psychiatry 2008;23:364-369
97. Caroff SN, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother 2007;7:423-431
98. Khaldi S, Kornreich C, Choubani Z, Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale 2008;34:618-624
99. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008;23 suppl 1:15-26.
100. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008;42:1290-1297
101. Kohen I, Gordon ML, Manu P. Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports. CNS Spectr 2007;12:596-598
102. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39.
103. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63-72.
104. Frenchman IB. Atypical antipsychotics for nursing home patients: a retrospective chart review. Drugs Aging 2005;22:257-264
105. Martin H, Slyk MP, Deymann S, Cornacchione MJ. Safety profile assessment of risperidone and olanzapine in longterm care patients with dementia. J Am Med Dir Assoc 2003;4:183-188
106. Cohen R, Wilkins KM, Ostroff R, Tampi RR. Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother 2007;5:241-246
107. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000;17:363-384
108. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765
109. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998;155:1521-1528
110. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425
111. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003;53:1142-1145
112. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589
113. Katz IR. Optimizing atypical antipsychotic treatment strategies in the elderly. J Am Geriatr Soc 2004;52:S272-7.
114. Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 2009;3:5-15.
115. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007;104:3456-3459
116. Lipkovich I, Ahl J, Nichols R, Hardy T, Poole Hoffmann V. Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances. J Geriatr Psychiatry Neurol 2007;20:107-114
117. Feldman PD, Hay LK, Deberdt W, et al. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 2004;5:38-46.
118. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-170
119. Lamberti JS, Costea GO, Olson D, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. J Clin Psychiatry 2005;66:900-906
120. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother 2008;42:1316-1322
121. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-480
122. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716
123. Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-1276
124. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
125. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006;23:937-956
126. Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G. The safety of clozapine in the elderly. Expert Opin Drug Saf 2008;7:525-538
127. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
128. Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics 2007;48:530-531
129. Stergiou V, Bozikas VP, Garyfallos G, Nikolaidis N, Lavrentiadis G, Fokas K. Olanzapine-induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:992-994
130. Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs 2006;20:217-225
131. Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007;68:929-934
132. Hien le TT, Cumming RG, Cameron ID, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005;53:1290-1295
133. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008;56:661-666
134. Rudolph JL, Gardner KF, Gramigna GD, McGlinchey RE. Antipsychotics and oropharyngeal dysphagia in hospitalized older patients. J Clin Psychopharmacol 2008;28:532-535
135. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002;25:91-110.
136. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61 suppl 8:14-7; discussion 18-19
137. Foster R, Olajide D. A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care. J Psychopharmacol 2005;19:93-96
138. Kinon BJ, Gilmore JA, LiuH,Halbreich UM.Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003;28 suppl 2:69-82.
139. Martin-Latry K, GoumyMP, Latry P, et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry 2007;22:335-338
140. vanMarum RJ,WegewijsMA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. Eur J Clin Pharmacol 2007;63:627-631
141. Shahzad S, Suleman MI, Shahab H, et al. Cataract occurrence with antipsychotic drugs. Psychosomatics 2002;43:354-359
142. Byerly MJ, Nakonezny PA, Bettcher BM, Carmody T, Fisher R, Rush AJ. Sexual dysfunction associated with secondgeneration antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006;86:244-250 (Pubitemid 44234038)
143. Putman L, Wang JT. The Closing Group: therapeutic recreation for nursing home residents with dementia and accompanying agitation and/or anxiety. Am J Alzheimers Dis Other Demen 2007;22:167-175
144. PassmoreMJ, Gardner DM, Polak Y, Rabheru K. Alternatives to atypical antipsychotics for the management of dementiarelated agitation. Drugs Aging 2008;25:381-398
145. APA Work Group on Alzheimer's Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al.; Steering Committee on Practice Guidelines,McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. AmJ Psychiatry 2007;164(12 suppl):5-56.
146. Ballard C, Brown R, Fossey J, et al. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatry 2009;17:726-733
147. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9:361-381
148. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15:942-952
149. Chemali Z, Chahine LM, Fricchione G. The use of selective serotonin reuptake inhibitors in elderly patients. Harv Rev Psychiatry 2009;17:242-253
150. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341-348 (Pubitemid 351549385)
151. Holmes C,Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-219
152. Howard RJ, Juszczak E, Ballard CG, et al; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1382-1392
153. Fischer C, Bozanovic R, Atkins JH, Rourke SB. Treatment of delusions in Alzheimer's disease-response to pharmacotherapy. Dement Geriatr Cogn Disord 2006;22:260-266